文献速递淋巴瘤

蛋氨酸代谢相关基因预后模型构建及靶向蛋氨酸代谢对弥漫大B细胞淋巴瘤的作用

[Construction of a methionine metabolism-related prognostic signature and the effect of targeting methionine metabolism on diffuse large B-cell lymphoma].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

研究基于GEO数据集GSE10846构建了由8个蛋氨酸代谢相关基因组成的DLBCL预后风险模型,并在GSE11318和GSE181063中验证。体外和体内实验表明,蛋氨酸剥夺可抑制DLBCL细胞增殖并诱导凋亡,蛋氨酸限制饮食可减小荷瘤小鼠肿瘤体积和重量。

要点

  • 8基因蛋氨酸代谢预后模型可区分DLBCL高低风险组,高风险组总生存更差。
  • 蛋氨酸剥夺完全抑制DLBCL细胞增殖并升高凋亡,补充蛋氨酸或SAM可恢复凋亡。
  • 蛋氨酸限制饮食可降低U2932荷瘤小鼠肿瘤体积和重量。

核心结论

  • 基于蛋氨酸代谢相关基因的预后风险模型对DLBCL具有预后预测潜力。
  • 蛋氨酸代谢异常可调控DLBCL细胞增殖与凋亡,为靶向蛋氨酸代谢干预提供实验依据。

研究设计与样本

  • 从GEO数据集GSE10846获取DLBCL患者预后信息及蛋氨酸代谢基因表达数据,用Lasso和Cox回归筛选核心基因并构建风险模型。
  • 模型在GSE11318和GSE181063数据集中验证。
  • 体外培养DLBCL细胞株U2932和SUDHL-4,设正常培养组、蛋氨酸剥夺组、蛋氨酸剥夺+蛋氨酸补充组、蛋氨酸剥夺+SAM补充组。
  • 构建U2932细胞荷瘤NOD-SCID小鼠模型,分为常规饮食对照组(n=5)和蛋氨酸限制性饮食组(n=5)。

主要发现

  • 从33个蛋氨酸代谢相关基因中筛选出8个核心基因构建预后风险模型。
  • 训练集Kaplan-Meier分析显示高风险组总生存较低风险组差(HR=2.50,95% CI:1.84~3.39,P<0.001)。
  • 验证集GSE11318(HR=1.89,95% CI:1.30~2.75,P<0.001)和GSE181063(HR=1.39,95% CI:1.20~1.62,P<0.001)验证了模型的稳定预后预测能力。
  • 体外实验显示,与对照组相比,蛋氨酸剥夺组细胞内蛋氨酸、SAM浓度降低(P值均<0.001),细胞增殖完全受抑且凋亡水平升高(P值均<0.001)。
  • 与蛋氨酸剥夺组相比,蛋氨酸补充组、SAM补充组细胞凋亡水平恢复(P值均<0.001)。

临床怎么用

  • 该8基因蛋氨酸代谢预后模型可用于DLBCL患者风险分层评估,但需进一步临床验证。
  • 靶向蛋氨酸代谢(如蛋氨酸剥夺或限制)可能成为DLBCL干预策略,尚需临床研究确认。

局限性

  • 预后模型基于公共数据集回顾性分析,缺乏前瞻性临床队列验证。
  • 体内实验样本量小(每组n=5),需扩大样本验证。
  • 蛋氨酸代谢干预的临床应用安全性和有效性尚未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To construct a prognostic risk model based on methionine metabolism-related genes in diffuse large B-cell lymphoma (DLBCL), investigate its prognostic significance, and clarify the regulatory role of abnormal methionine metabolism in DLBCL progression. Methods: Clinical prognostic information and methionine metabolism-related gene expression data of patients with DLBCL were obtained from the GEO dataset GSE10846. Lasso regression and Cox regression analyses were performed to screen core prognostic genes and establish a risk model, which was further validated in GSE11318 and GSE181063 datasets. The potential biological functions were analyzed by using Gene Ontology, Kyoto Encyclopedia of Genes and Genomes pathway analysis, and Gene Set Enrichment Analysis. The DLBCL cell lines U2932 and SUDHL-4 were cultured in vitro and divided into the normal culture group (control group), methionine deprivation group, methionine deprivation + methionine supplementation group (methionine supplementation group), and methionine deprivation + S-adenosylmethionine (SAM) supplementation group (SAM supplementation group). Intracellular concentrations of methionine and SAM were detected by liquid chromatography-mass spectrometry. Cell proliferation and apoptosis were measured by using CCK-8 assay and flow cytometry, respectively. A U2932 cell-derived xenograft model was established in NOD-SCID mice, which were assigned to the control diet group (n=5) and methionine-restricted diet group (n=5), and tumor growth was monitored dynamically. Results: Eight core genes were screened from 33 methionine metabolism-related genes to construct the prognostic risk model. Kaplan-Meier analysis in the training set revealed that overall survival was significantly shorter in the high-risk group than in the low-risk group (HR=2.50, 95% CI: 1.84-3.39, P<0.001). Stable prognostic performance was confirmed in two validation sets: GSE11318 (HR=1.89, 95% CI: 1.30-2.75, P<0.001) and GSE181063 (HR=1.39, 95% CI: 1.20-1.62, P<0.001). In vitro, compared with the normal culture group, the methionine deprivation group showed significantly decreased intracellular levels of methionine and SAM (both P<0.001), completely inhibited cell proliferation, and increased apoptosis (both P<0.001); compared with the methionine deprivation group, the methionine supplementation group and SAM supplementation group exhibited significantly restored apoptosis (all P value <0.001). In vivo, methionine restriction evidently reduced tumor volume [ (438.3±179.1) mm(3) vs (1 451.0±464.9) mm(3), P=0.002] and tumor weight [ (0.3±0.1) g vs (1.1±0.4) g, P=0.004] compared with the control diet. Conclusion: The prognostic risk model based on methionine metabolism-related genes shows potential prognostic value for DLBCL. Abnormal methionine metabolism regulates the proliferation and apoptosis of DLBCL cells, providing experimental evidence for the intervention targeting methionine metabolism in DLBCL. 目的: 构建基于蛋氨酸代谢相关基因的预后风险模型,探究其在弥漫大B细胞淋巴瘤(DLBCL)中的预后评估价值以及蛋氨酸代谢异常在DLBCL疾病进展中的调控作用。 方法: 从GEO数据集(GSE10846)获取DLBCL患者预后信息及蛋氨酸代谢基因表达数据,采用Lasso回归分析和Cox回归分析筛选核心预后基因并构建风险模型,以GSE11318和GSE181063数据集验证模型可靠性。通过基因本体(GO)、京都基因与基因组百科全书(KEGG)通路分析和基因集富集分析(GSEA)解析模型潜在生物学功能。体外培养DLBCL细胞株U2932和SUDHL-4,设置正常培养组(对照组)、蛋氨酸剥夺组、蛋氨酸剥夺+蛋氨酸补充组(蛋氨酸补充组)、蛋氨酸剥夺+S-腺苷蛋氨酸(SAM)补充组(SAM补充组),采用液相色谱-串联质谱(LC-MS)检测细胞内蛋氨酸、SAM浓度,CCK-8实验和流式细胞术分别检测细胞增殖活性与凋亡水平。构建U2932细胞荷瘤NOD-SCID小鼠模型,分为常规饮食对照组(5只)、蛋氨酸限制性饮食组(5只),动态监测肿瘤生长情况。 结果: 从33个蛋氨酸代谢相关基因中筛选出8个核心基因构建预后风险模型,训练集Kaplan-Meier分析显示,高风险组患者总生存较低风险组差(HR=2.50,95% CI:1.84~3.39,P<0.001),验证集GSE11318(HR=1.89,95% CI:1.30~2.75,P<0.001)、GSE181063(HR=1.39,95% CI:1.20~1.62,P<0.001)验证了模型的稳定预后预测能力。体外实验显示,与对照组相比,蛋氨酸剥夺组细胞内蛋氨酸、SAM浓度降低(P值均<0.001),细胞增殖完全受抑且凋亡水平升高(P值均<0.001);与蛋氨酸剥夺组相比,蛋氨酸补充组、SAM补充组细胞凋亡水平恢复(P值均<0.001)。动物实验显示,与对照相比,蛋氨酸限制性饮食组小鼠肿瘤体积[(438.3±179.1)mm(3)对(1 451.0±464.9)mm(3),P=0.002]、肿瘤重量[(0.3±0.1)g对(1.1±0.4)g,P=0.004]均降低。 结论: 基于蛋氨酸代谢相关基因构建的预后风险模型具有DLBCL预后预测潜力,且蛋氨酸代谢异常可调控DLBCL细胞增殖与凋亡,为靶向蛋氨酸代谢的DLBCL干预研究提供了实验依据。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang BY, Gu MF, Li JY, et al. [Construction of a methionine metabolism-related prognostic signature and the effect of targeting methionine metabolism on diffuse large B-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42409736. doi:10.3760/cma.j.cn121090-20251219-00603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。